TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30329175

Group type: COMPARATOR
Intervention: Intravenous Immunoglobulin (IVIG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange (TPE)
Number of subjects: 40
Study: 27693836

Group type: EXPERIMENTAL
Intervention: Pressure ulcer prevention care bundle
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1600
Study: 24485800

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg) combined with cognitive training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo combined with cognitive training
Number of subjects: 33
Study: 22409711

Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: UVA1 (moderate dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: UVA1 (low dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: UVA1 (both doses)
Number of subjects: 40
Study: 20884414

Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent with bioabsorbable coating (SES)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 95
Study: 17405806

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Neurological Rehabilitation (NR)
Number of subjects: 19
Study: 16619801

Group type: EXPERIMENTAL
Intervention: Color Doppler imaging in preterm infants
Number of subjects: 55

Group type: COMPARATOR
Intervention: Color Doppler imaging in full-term infants
Number of subjects: 55
Study: 12171430

Group type: EXPERIMENTAL
Intervention: TML liquid diet (20 g/d)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Soybean oil liquid diet (20 g/d)
Number of subjects: 6
Study: 9854601

Group type: EXPERIMENTAL
Intervention: DDAVP plus behavioral therapy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Behavioral therapy plus placebo
Number of subjects: 226

Group type: COMPARATOR
Intervention: DDAVP alone
Number of subjects: 226
Study: 8570776

Group type: EXPERIMENTAL
Intervention: Naltrexone 40 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1319874

Group type: EXPERIMENTAL
Intervention: Cimetidine 400mg 3 times daily for 8 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: No cimetidine (control group)
Number of subjects: 12
Study: 6370028

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1-2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (10-20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triflupromazin (10-20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pethidin (50-100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphin (0.15-0.3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droperidol (2.5-5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 0
Study: 30481272

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 30145513

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Oral aripiprazole
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 27806551

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Health Belief Model (HBM) to reduce salt consumption
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 200
Study: 24841774

Group type: EXPERIMENTAL
Intervention: PAR (Public Access Resuscitator)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 71
Study: 22035500

Group type: EXPERIMENTAL
Intervention: Small-bowel capsule endoscopy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adequate antiallergic treatment
Number of subjects: 15
Study: 20552571

Group type: EXPERIMENTAL
Intervention: Consistency‐Adjusted Alpha‐Adaptive Strategy (CAAAS)
Number of subjects: 0
Study: 17490956

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g EPA+DHA/d) for either 7, 14, or 21 days before surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (10 mL/d for 21 days before surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olive oil (10 mL/d for 21 days before surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 0
Study: 16182145

Group type: EXPERIMENTAL
Intervention: Adult Identity Mentoring (AIM) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard health education control curriculum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AIM intervention (male participants)
Number of subjects: 20
Study: 11966665

Group type: COMPARATOR
Intervention: Tezosentan infusion at 100 mg h(‐1) for 6 h (study A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tezosentan infusion at 5 mg h(‐1) for 72 h (study B)
Number of subjects: 14
Study: 9150773

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with adrenaline (30 ml)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline (30 ml)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no infiltration)
Number of subjects: 29
Study: 7965153

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) pacing
Number of subjects: 20
Study: 3440106

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times daily for 10 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control state (single dose of CBZ 400 mg)
Number of subjects: 7
Study: 29462657

Group type: EXPERIMENTAL
Intervention: Serlopitant 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serlopitant 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27914504

Group type: EXPERIMENTAL
Intervention: Ezetimibe (Ez) 10 mg/d with Simvastatin (S) 40 mg/d (Ez/S)
Number of subjects: 17706

Group type: COMPARATOR
Intervention: Placebo with Simvastatin 40 mg/d (P/S)
Number of subjects: 17706
Study: 24444992

Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure (NIBP) measurement in the arm
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure (NIBP) measurement in the forearm
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure (NIBP) measurement in the ankle
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Initial three NIBP measurements
Number of subjects: 101
Study: 22668768

Group type: EXPERIMENTAL
Intervention: Short-term therapeutic conversation intervention (n = 41)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional care (control group, n = 35)
Number of subjects: 76
Study: 20105282

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Combination of AQ and SP (AQ+SP)
Number of subjects: 760
Study: 18086006

Group type: EXPERIMENTAL
Intervention: E alone (‐T, +E)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both (+T, +E)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sex steroid deficiency (‐T, ‐E)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: E effects on bone resorption
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: E effects on RANKL mRNA levels
Number of subjects: 59
Study: 15905081

Group type: EXPERIMENTAL
Intervention: DCBT1234‐Lung KR
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: salbutamol+theophylline+bromhexine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 14712099

Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal (TEP) hernia repair
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lichtenstein hernia repair (LHR)
Number of subjects: 26
Study: 11083305

Group type: EXPERIMENTAL
Intervention: Upper limb isometric contraction at 50% maximum force
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Upper limb isometric contraction at 100% maximum force
Number of subjects: 10
Study: 8775571

Group type: EXPERIMENTAL
Intervention: Pedal cadence of 70 rpm
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pedal cadence of 90 rpm
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pedal cadence of 110 rpm
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pedal cadence of 70, 90, and 110 rpm
Number of subjects: 7
Study: 1347955

Group type: EXPERIMENTAL
Intervention: 2.4 mg FTC nicotine cigarettes
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1.0 mg FTC nicotine cigarettes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nicotine-free cigarettes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: QSDS smoking
Number of subjects: 12
Study: 3920770

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms 4 times a day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms 4 times a day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cimetidine 300 mg 4 times a day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Misoprostol high-dose (200 micrograms 4 times a day)
Number of subjects: 66
Study: 30486574

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dosage 0.5 μg/kg, continuous infusion 0.2 μg·kg(‐1)·h(‐1) until 30 minutes before the end of operation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study: 27272161

Group type: EXPERIMENTAL
Intervention: Fluticasone 125 μg + formoterol 5 μg in the same device
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluticasone 125 μg + formoterol 12 μg as needed
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluticasone 250 μg + formoterol 12 μg as needed
Number of subjects: 36
Study: 24657956

Group type: EXPERIMENTAL
Intervention: Yoga training (1-hour sessions, 2 times per week for 3 months)
Number of subjects: 20
Study: 22219023

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 182

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 182

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 182
Study: 20035039

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVFX) 500 mg single oral dose
Number of subjects: 40
Study: 18937899

Group type: EXPERIMENTAL
Intervention: Supplementation with EPA and DHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased consumption of marine omega-3 fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased intake of EPA and DHA
Number of subjects: 0
Study: 15853102

Group type: COMPARATOR
Intervention: Air‐powder polishing (PJ)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotating brush with pumice‐water slurry (PB)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotating rubber cup with prophylaxis paste (PP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotating rubber cup with pumice‐water slurry (PC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotating rubber cup with prophylaxis gel (PG)
Number of subjects: 48
Study: 12126375

Group type: EXPERIMENTAL
Intervention: Guidor bioresorbable membrane
Number of subjects: 25

Group type: COMPARATOR
Intervention: No membrane used (Control)
Number of subjects: 25
Study: 10396795

Group type: EXPERIMENTAL
Intervention: Patient education methods
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Baseline cotinine value
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Duration of smoking habit
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Exposure to environmental tobacco smoke
Number of subjects: 435
Study: 7485938

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia and midazolam (0.05 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spinal anaesthesia only
Number of subjects: 20
Study: 2249377

Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate (10, 30, 50 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NDMAD mesylate (10, 30, 50 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adinazolam and NDMAD mesylate
Number of subjects: 6
Study: 414773

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30621746

Group type: EXPERIMENTAL
Intervention: Reduced-dose TNF inhibitors (approximately half of the full dose)
Number of subjects: 126
Study: 27702622

Group type: EXPERIMENTAL
Intervention: DSAEK with active air infusion system
Number of subjects: 173

Group type: COMPARATOR
Intervention: DSAEK without active air infusion system
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 173
Study: 26445094

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (125 mg/m²) plus gemcitabine (1000 mg/m²) given on days 1, 8, and 15 every 28 days
Number of subjects: 114

Group type: COMPARATOR
Intervention: nab-paclitaxel (125 mg/m²) plus sLV5FU2 (leucovorin 400 mg/m² followed by bolus 400 mg/m² 5-fluorouracil and by 5-fluorouracil 2400 mg/m² as an 46-h intravenous infusion) given on days 1 and 15 every 28 days
Number of subjects: 114
Study: 23825656

Group type: EXPERIMENTAL
Intervention: Condition A (continuous transdermal alcohol monitoring anklet, no alcohol consumption for 14 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Condition B (no alcohol consumption for 14 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Condition C (anklet, continued alcohol consumption as normal)
Number of subjects: 60
Study: 20670293

Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC) 100 mg initial dose followed by 50 mg every 12 h
Number of subjects: 473

Group type: COMPARATOR
Intervention: Ceftriaxone (CTX) 2 g once daily plus Metronidazole (MET) 1-2 g daily
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Ceftriaxone (CTX) plus Metronidazole (MET)
Number of subjects: 473
Study: 18298424

Group type: EXPERIMENTAL
Intervention: MAS063DP
Number of subjects: 60

Group type: COMPARATOR
Intervention: MAS060
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 60
Study: 16879213

Group type: EXPERIMENTAL
Intervention: PTGER2 2-1-1 haplotype
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: PTGER2 2-2-1 haplotype
Number of subjects: 1200

Group type: COMPARATOR
Intervention: PTGS2 polymorphisms/haplotypes
Number of subjects: 1200
Study: 12811360

Group type: EXPERIMENTAL
Intervention: Methotrexate (low dose, 6 oral doses of 30 mg/m2; high dose, 1 g/m2 intravenously) followed by intravenous mercaptopurine (1 g/m2 over a 6-hour period)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Mercaptopurine alone (1 g/m2 over a 6-hour period)
Number of subjects: 233
Study: 11018616

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 8888844

Group type: EXPERIMENTAL
Intervention: Dilated fundus examination
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nondilated fundus examination
Number of subjects: 90
Study: 1893906

Group type: EXPERIMENTAL
Intervention: 3 mg.kg‐1 body weight of caffeine (C3)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5 mg.kg‐1 body weight of caffeine (C5)
Number of subjects: 17

Group type: COMPARATOR
Intervention: gelatin capsule (C)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: C3 and C5 treatments
Number of subjects: 17
Study: 6844372

Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study: 29391380

Group type: EXPERIMENTAL
Intervention: Protein-enriched, milk-based supplements (27.5 g whey protein/day)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Isoenergetic placebo products (<1.5 g protein/day)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups offered a standardised resistance training programme
Number of subjects: 165
Study: 27590454

Group type: EXPERIMENTAL
Intervention: Low-level laser treatment at auriculotherapy points
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-level laser simulation (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-level laser treatment
Number of subjects: 45
Study: 25139516

Group type: EXPERIMENTAL
Intervention: Premium hearing aids
Number of subjects: 25

Group type: COMPARATOR
Intervention: Basic hearing aids
Number of subjects: 25
Study: 23935745

Group type: EXPERIMENTAL
Intervention: Porcine acellular dermal xenograft (ADX) in combination with autologous split‐thickness skin grafting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pure autologous split‐thickness skin grafting
Number of subjects: 30
Study: 21296333

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg b.i.d.
Number of subjects: 4608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4608
Study: 18495806

Group type: EXPERIMENTAL
Intervention: Valproate (Depakine‐Chrono) 3000 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17168254

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of lithium and T3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12899645

Group type: EXPERIMENTAL
Intervention: IFN alpha plus ribavirin (group A: 29 patients)
Number of subjects: 62

Group type: COMPARATOR
Intervention: IFN alpha (group B: 33 patients)
Number of subjects: 62
Study: 10764301

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional Management (CM)
Number of subjects: 78
Study: 8996846

Group type: EXPERIMENTAL
Intervention: i.v. infusion of adrenaline (1 microgram/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: i.v. infusion of isoprenaline (1 microgram/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: i.v. infusion of isoprenaline (1 microgram/min) with pretreatment with 100 mg talinolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p.o. administration of 1200 mg celiprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p.o. administration of 0.4 mg bimakalim
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p.o. administration of PDE-III inhibitors meribendan and isomazole
Number of subjects: 0
Study: 1617519

Group type: EXPERIMENTAL
Intervention: Rescue PTCA
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Reperfusion achieved
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: No reperfusion achieved
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anterior myocardial infarction with reperfusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Anterior myocardial infarction without reperfusion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inferior myocardial infarction with reperfusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Inferior myocardial infarction without reperfusion
Number of subjects: 28
Study: 6361284

Group type: EXPERIMENTAL
Intervention: Oral etretinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29095358

Group type: EXPERIMENTAL
Intervention: Oral spironolactone treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 41
Study: 29984418

Group type: EXPERIMENTAL
Intervention: Unguided internet cognitive-behavioral treatment (ICBT) for perfectionism
Number of subjects: 67
Study: 26242288

Group type: COMPARATOR
Intervention: 0 mg nicotine gum
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 30 mg menthol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine + 30 mg menthol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Menthol (in general)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Menthol (in half of participants)
Number of subjects: 42
Study: 24918789

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin (both doses)
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin with background sulfonylurea
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin without background sulfonylurea
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study: 22840866

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.8 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20399815

Group type: EXPERIMENTAL
Intervention: Bad news consultation (BN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: History taking consultation (HT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reading aloud
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-reported stress (STAI and VAS)
Number of subjects: 20
Study: 17511194

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 100
Study: 16613275

Group type: EXPERIMENTAL
Intervention: Clozapine (CZ) combined with electroacupuncture (EA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clozapine (CZ) alone
Number of subjects: 90
Study: 12937858

Group type: EXPERIMENTAL
Intervention: Oral suspension of megestrol acetate (MA) at a daily dose of 480-840 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral suspension of megestrol acetate (MA)
Number of subjects: 22
Study: 11732527

Group type: EXPERIMENTAL
Intervention: Propofol 15 microg kg(‐1) min(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol 20 microg kg(‐1) min(‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Intralipid 1 ml h(‐1))
Number of subjects: 100